The emergence of resistance to first-generation tyrosine kinase inhibitors (TKIs) has been a significant limitation in the long-term management of cancers driven by aberrant tyrosine kinase signaling, including HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.